Evidence map›Paper›PMID 30050770›Full record

ReviewTranslational lung cancer research2018

Blood based biomarkers beyond genomics for lung cancer screening.

Samir M Hanash, Edwin Justin Ostrin, Johannes F Fahrmann

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational lung cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Non-small-cell lung cancer.Nature reviews. Disease primers · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Contemporary issues in the implementation of lung cancer screening.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  13. Observational
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Samir M HanashDepartment of Clinical Cancer Prevention, MD Anderson Cancer Center, Houston, TX, USA.
Edwin Justin OstrinDepartment of Pulmonary Medicine, MD Anderson Cancer Center, Houston, TX, USA.
Johannes F FahrmannDepartment of Clinical Cancer Prevention, MD Anderson Cancer Center, Houston, TX, USA.

Funding

Development of Risk and Early Detection Biomarker for Small Cell Lung CancerU01CA213285 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HANASH, SAMIR M · 2017 to 2021
$2.6M
NCI NIH HHS U01 CA213285
6 · The paper itself

Abstract

While there is considerable interest at the present time in the development of so-called liquid biopsy approaches for cancer detection based notably on circulating tumor DNA, there are other types of potential biomarkers that show promise for lung cancer screening and early detection. Here we review approaches and some of the promising markers based on proteomics, metabolomics and the immune response to tumor antigens in the form of autoantibodies.

Indexed as

autoantibodiesBiomarkersmetabolitesproteins

Identifiers

PMID30050770
PMCPMC6037962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.